Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
November 30, 2022 21:29 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Runway Growth Finance Corp. Prices Offering of 8.00% Notes due 2027
November 30, 2022 19:41 ET
|
Runway Growth Finance Corp.
WOODSIDE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (the “Company”) (Nasdaq: RWAY), an externally managed business development company, today announced that it has priced...
Onica by Rackspace Technology Achieves the AWS Service Delivery Designation for AWS Glue
November 30, 2022 19:10 ET
|
Rackspace Technology, Inc.
SAN ANTONIO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Rackspace Technology® (NASDAQ: RXT) — a leading end-to-end, multicloud technology solutions company, today announced that Onica by Rackspace...
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
November 30, 2022 19:05 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused...
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
November 30, 2022 18:10 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
November 30, 2022 18:05 ET
|
Achilles Therapeutics PLC
- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results...
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
November 30, 2022 18:05 ET
|
Oncocyte Corporation
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces Executive Leadership Changes
November 30, 2022 18:00 ET
|
Oncocyte Corporation
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2022 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2022...
DIRTT Announces the Closing of Private Placement
November 30, 2022 17:42 ET
|
DIRTT Environmental Solutions
CALGARY, Alberta, Nov. 30, 2022 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX:DRT, NASDAQ:DRTT), a global leader in industrialized construction, is pleased...